These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8515717)

  • 41. Is it pathological to be female? Oestrogen deficiency symptoms in 847 women aged 15 to 69 years.
    Dietsch E
    Aust J Adv Nurs; 1994 Dec-1995 Feb; 12(2):8-13. PubMed ID: 7755937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study.
    MacLennan AH; Henderson VW; Paine BJ; Mathias J; Ramsay EN; Ryan P; Stocks NP; Taylor AW
    Menopause; 2006; 13(1):28-36. PubMed ID: 16607096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Postmenopausal hormone replacement therapy use by older Mexican-American women.
    Newell DA; Markides KS; Ray LA; Freeman JL
    J Am Geriatr Soc; 2001 Aug; 49(8):1046-51. PubMed ID: 11555065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patterns and correlates of hormone replacement therapy use among middle-aged Australian women.
    France K; Schofield MJ; Lee C
    Womens Health; 1997; 3(2):121-38. PubMed ID: 9332154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates.
    Levi F; La Vecchia C; Gulie C; Franceschi S; Negri E
    Eur J Cancer; 1993; 29A(10):1445-9. PubMed ID: 8398274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hormone replacement and menopausal symptoms following hysterectomy.
    Langenberg P; Kjerulff KH; Stolley PD
    Am J Epidemiol; 1997 Nov; 146(10):870-80. PubMed ID: 9384207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Self-reported prevalence of prostate-specific antigen testing in South Australia: a community study.
    Pinnock CB; Weller DP; Marshall VR
    Med J Aust; 1998 Jul; 169(1):25-8. PubMed ID: 9695698
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Female hormone utilisation and risk of hepatocellular carcinoma.
    Tavani A; Negri E; Parazzini F; Franceschi S; La Vecchia C
    Br J Cancer; 1993 Mar; 67(3):635-7. PubMed ID: 8382515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of low-energy hip, wrist, and upper arm fractures among current and previous users of hormone replacement therapy: The Danish Nurse Cohort Study.
    Hundrup YA; Høidrup S; Ekholm O; Davidsen M; Obel EB
    Eur J Epidemiol; 2004; 19(12):1089-95. PubMed ID: 15678788
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Associations between the use of complementary and alternative medications and demographic, health and lifestyle factors in mid-life Australian women.
    Gollschewski S; Anderson D; Skerman H; Lyons-Wall P
    Climacteric; 2005 Sep; 8(3):271-8. PubMed ID: 16390759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment.
    Pasquali R; Gambineri A; Anconetani B; Vicennati V; Colitta D; Caramelli E; Casimirri F; Morselli-Labate AM
    Clin Endocrinol (Oxf); 1999 Apr; 50(4):517-27. PubMed ID: 10468913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hormone replacement therapy in the developing countries.
    Oei PL; Ratnam SS
    Aust N Z J Obstet Gynaecol; 1998 May; 38(2):141-4. PubMed ID: 9653846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of advance directives by South Australians: results from the Health Omnibus Survey Spring 2012.
    Bradley SL; Woodman RJ; Tieman JJ; Phillips PA
    Med J Aust; 2014 Oct; 201(8):467-9. PubMed ID: 25332034
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low use of effective and safe therapies for moderate to severe menopausal symptoms: a cross-sectional community study of Australian women.
    Worsley R; Bell RJ; Gartoulla P; Davis SR
    Menopause; 2016 Jan; 23(1):11-7. PubMed ID: 26240945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
    Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
    Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence and impact of vaginal symptoms among postmenopausal women.
    Santoro N; Komi J
    J Sex Med; 2009 Aug; 6(8):2133-42. PubMed ID: 19493278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women.
    Seed M; Sands RH; McLaren M; Kirk G; Darko D
    Fam Pract; 2000 Dec; 17(6):497-507. PubMed ID: 11120722
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hormone therapies in women aged 40 and older: prevalence and correlates of use.
    Carney PA; Tosteson AN; Titus-Ernstoff L; Weiss JE; Goodrich ME; Manganiello P; Kasales CJ
    Maturitas; 2006 Jan; 53(1):65-76. PubMed ID: 16325024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Case-control study of oestrogen replacement therapy and risk of cervical cancer.
    Parazzini F; La Vecchia C; Negri E; Franceschi S; Moroni S; Chatenoud L; Bolis G
    BMJ; 1997 Jul; 315(7100):85-8. PubMed ID: 9240046
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response of plasma low density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause.
    Griffin B; Farish E; Walsh D; Barnes J; Caslake M; Shepherd J; Hart D
    Clin Endocrinol (Oxf); 1993 Oct; 39(4):463-8. PubMed ID: 8287573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.